Compare TDW & IBRX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | TDW | IBRX |
|---|---|---|
| Founded | 1956 | 2014 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Marine Transportation | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 2.7B | 2.3B |
| IPO Year | N/A | N/A |
| Metric | TDW | IBRX |
|---|---|---|
| Price | $57.67 | $2.31 |
| Analyst Decision | Hold | Strong Buy |
| Analyst Count | 3 | 6 |
| Target Price | ★ $67.50 | $9.83 |
| AVG Volume (30 Days) | 936.3K | ★ 10.5M |
| Earning Date | 11-10-2025 | 11-04-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | ★ 2.97 | N/A |
| Revenue | ★ $1,361,073,000.00 | $82,555,000.00 |
| Revenue This Year | $0.76 | $667.18 |
| Revenue Next Year | $0.81 | $88.32 |
| P/E Ratio | $19.42 | ★ N/A |
| Revenue Growth | 4.42 | ★ 1025.95 |
| 52 Week Low | $31.17 | $1.83 |
| 52 Week High | $64.07 | $5.12 |
| Indicator | TDW | IBRX |
|---|---|---|
| Relative Strength Index (RSI) | 57.12 | 53.74 |
| Support Level | $53.38 | $2.06 |
| Resistance Level | $55.36 | $2.34 |
| Average True Range (ATR) | 2.83 | 0.15 |
| MACD | 0.38 | 0.03 |
| Stochastic Oscillator | 73.19 | 64.13 |
Tidewater Inc provides marine and transportation services to the offshore energy industry. The company's vessels and associated services support all phases of offshore crude oil and natural gas (also referred to as oil and gas) exploration activities, field development, production, and maintenance, as well as windfarm development and maintenance. Its services include towing and anchor handling for mobile offshore drilling units; transporting supplies and personnel necessary to sustain drilling, workovers, production activities, field abandonment, dismantlement, and restoration activities; and Others. The group manages its business through five segments including the Americas, Asia Pacific, Middle East, Europe/Mediterranean, and West Africa.
ImmunityBio Inc is an integrated clinical-stage biotechnology company discovering, developing, and commercializing next-generation immuno- and cellular therapies that bolster the natural immune system to drive and sustain an immune response. Its platforms for the development of biologic product candidates include (i) antibody-cytokine fusion proteins, (ii) DNA, RNA, and recombinant protein vaccines, and (iii) cell therapies. Its focus includes bladder, lung, and colorectal cancers and GBM and its product candidate Anktiva is an IL-15 superagonist antibody-cytokine fusion protein. It has two geographical segments: the United States and Europe. Key revenue is generated from the United States.